Design Therapeutics, Inc. (DSGN)
NASDAQ · Manufacturing · Pharmaceutical preparations
$12.12−$0.1200 (−0.98%) on the dayAs of the close; data may be delayed.
DSGN price, last 12 months
Key stats
- Previous close
- $12.24
- Open
- $12.29
- Day range
- $11.97 – $12.51
- 52-week range
- $5.28 – $17.25
- Volume
- 434.5K
- Avg volume (20 days)
- 796.3K
- Market cap
- $758.5M
Performance
1W−1.0%
1M−22.3%
3M−9.2%
6M+13.2%
YTD+29.2%
1Y+88.2%
vs S&P 500, 1Y+71.4 pts
Technicals and fundamentals
About Design Therapeutics, Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $758.5M